Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review describes the variety of mucocutaneous side effects caused by antineoplastic chemotherapy, with emphasis on skin, nails, and mucous membranes, while highlighting potential severity and the possibility of needing to adjust or interrupt treatment in rare cases; it presents no new clinical results.

This article discusses the importance of interpreting laboratory data and performing physical assessments to support pharmacists in clinical decision-making and patient consultations, but reports no new empirical findings.

This study reported an unusual case of nail matrix involvement and trachyonychia in a child with juvenile pityriasis rubra pilaris, showing significant improvement with topical therapy and oral biotin.

This study reports that the Pfizer-BioNTech COVID-19 vaccine showed 52% protection against COVID-19 after the first dose and 95% after the second in phase 3 trials.

This review explores the biomechanical factors and signaling systems, like Wnt, involved in the pathophysiology of psoriatic nail lesions and reports no new results.

This study suggests that onychopapilloma may originate from the nail bed rather than the nail matrix, with nail bed-related keratins and HK31 potentially serving as diagnostic markers.

This study examined the dermoscopic features of five patients with tuberous sclerosis and found that dermoscopy can differentiate characteristic cutaneous features from similar conditions, potentially aiding in earlier diagnosis when other symptoms are subtle or absent.

This study reported that immunotherapy in cancer patients can lead to skin-related immune adverse events, such as rashes, pruritus, and vitiligo, affecting a substantial proportion of patients.

This retrospective study found a variety of dermatological adverse events associated with antineoplastic treatments, often leading to changes or suspension of cancer therapies in affected patients.

This review covers the diverse cutaneous and systemic presentations of sarcoidosis in patients with skin of color, emphasizing the importance of early recognition to improve outcomes despite a generally poorer prognosis compared to Caucasians.

This article reviews how skin manifestations can aid in diagnosing various systemic diseases, focusing primarily on their association with rheumatologic conditions while also addressing vascular, granulomatous, and other disease impacts, aiming to provide dermatologists with practical diagnostic insights.

This review discusses the causes of nail pitting in children and adolescents, noting that while most cases are idiopathic, significant associations exist with conditions like psoriasis, juvenile arthritis, and alopecia areata, among others.

This expert consensus statement highlights that while targeted cancer therapies significantly improve patient survival, they often result in various skin toxicities, underscoring the need for early diagnosis, management, and multidisciplinary care to maintain patients' quality of life and ensure treatment continuity.

This chapter reviews skin manifestations in common rheumatic diseases, particularly those with polyarthritis, and offers a differential diagnosis of erythema nodosum without presenting new research findings.

This editorial summarizes key dermatological insights and learnings from the 2022 Dermatology Nurses' Association Convention, covering conditions like lichen sclerosus and melanoma, and issues related to nail disorders and skin of color.

This review discusses various dermatological scoring systems used to objectively assess disease severity and guide treatment decisions, reporting no new clinical results.

This case report describes a unique dermatologic condition called SCRATCH, occurring in a runner due to shirt friction, which resulted in clumped axillary hairs and temporary alopecia.

Early subungual melanoma might be treated with less aggressive surgery because it invades the skin under the nail more slowly.

This publication involves a case-series report on the treatment of male and female pattern hair loss using sublingual minoxidil in 64 patients, but it does not include an abstract or results.

In this study, sublingual tofacitinib achieved a longer estimated half-life than oral administration in treatment-resistant alopecia areata patients, potentially supporting daily dosing; overall treatment response was modest.

In this phase 1B clinical trial, sublingual minoxidil was tested for its effects on male and female pattern hair loss in a randomized, double-blind, placebo-controlled setting, but the abstract does not provide specific results or conclusions.

In this study, sublingual minoxidil was found to be a safe and effective treatment for increasing hair growth in transgender individuals with mild androgenetic alopecia who are undergoing full-dose testosterone therapy.

This study found that finite element analysis-guided design improved bubble microneedles' controlled tip separation and insertion strength, supporting effective transdermal and sublingual drug delivery.

This study developed a co-design framework using finite element analysis to optimize bubble microneedles, achieving controlled tip separation and effective drug delivery through the skin and mucosa while maintaining insertion strength.

This study introduces a co-design framework using finite element analysis to optimize separable bubble microneedles, demonstrating enhanced transdermal and sublingual drug delivery in preclinical models. In vivo results showed faster hair regrowth and glucose lowering in animals, indicating potential improvements over traditional methods.

This study reports a 10-year-old boy with ectodermal dysplasia and progressive balding experienced reduced hair shedding and increased hair density after four months of sublingual minoxidil treatment, without side-effects.

This review reports that topical minoxidil remains the primary treatment for androgenetic alopecia, while oral and sublingual forms offer alternative options, each with varying efficacy and side effects.

Sublingual minoxidil significantly improves hair growth in transgender individuals on testosterone therapy.

In this randomized, controlled trial, the researchers observed that sub-lingual minoxidil at doses of 1.35 mg and 4.05 mg, but not 0.45 mg, significantly increased hair fibre diameter in men with male androgenetic alopecia over 24 weeks, suggesting a dose-dependent reversal of follicle miniaturization.

This study found that both sublingual and oral minoxidil at 5 mg per day increased hair density similarly in men with androgenetic alopecia over 24 weeks, but sublingual administration was associated with fewer palpitations.